These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 23623266

  • 21. T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis.
    Rieder F, Nonevski I, Ma J, Ouyang Z, West G, Protheroe C, DePetris G, Schirbel A, Lapinski J, Goldblum J, Bonfield T, Lopez R, Harnett K, Lee J, Hirano I, Falk G, Biancani P, Fiocchi C.
    Gastroenterology; 2014 May; 146(5):1266-77.e1-9. PubMed ID: 24486052
    [Abstract] [Full Text] [Related]

  • 22. Esophageal functional impairments in experimental eosinophilic esophagitis.
    Mavi P, Rajavelu P, Rayapudi M, Paul RJ, Mishra A.
    Am J Physiol Gastrointest Liver Physiol; 2012 Jun 01; 302(11):G1347-55. PubMed ID: 22361731
    [Abstract] [Full Text] [Related]

  • 23. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.
    Gut; 2010 Jan 01; 59(1):21-30. PubMed ID: 19828470
    [Abstract] [Full Text] [Related]

  • 24. Optimal Biopsy Protocol to Evaluate Histological Effectiveness of Proton Pump Inhibitor Therapy in Patients with Eosinophilic Esophagitis.
    Fujiwara Y, Hashimoto A, Uemura R, Sawada A, Otani K, Tanaka F, Yamagami H, Tanigawa T, Watanabe T, Kabata D, Kuwae Y, Shintani A, Ohsawa M.
    Digestion; 2019 Jan 01; 100(1):64-71. PubMed ID: 30408792
    [Abstract] [Full Text] [Related]

  • 25. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
    Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, Lowichik A, Chen X, Emerson L, Cox K, O'Gorman MA, Peterson KA.
    Gastroenterology; 2014 Sep 01; 147(3):602-9. PubMed ID: 24907494
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis.
    Wong ECL, Gleave AL, Marshall JK, Narula N.
    Eur J Gastroenterol Hepatol; 2023 Oct 01; 35(10):1131-1136. PubMed ID: 37577798
    [Abstract] [Full Text] [Related]

  • 29. Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis.
    Wright BL, Doyle AD, Shim KP, Pai RK, Barshow SM, Horsley-Silva JL, Luo H, Rank MA, Jacobsen EA, Katzka DA, Kita H, Dellon ES.
    Dig Dis Sci; 2021 Mar 01; 66(3):775-783. PubMed ID: 32248390
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pathogenic role of mast cells in experimental eosinophilic esophagitis.
    Niranjan R, Mavi P, Rayapudi M, Dynda S, Mishra A.
    Am J Physiol Gastrointest Liver Physiol; 2013 Jun 15; 304(12):G1087-94. PubMed ID: 23599040
    [Abstract] [Full Text] [Related]

  • 32. Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice.
    Judd LM, Heine RG, Menheniott TR, Buzzelli J, O'Brien-Simpson N, Pavlic D, O'Connor L, Al Gazali K, Hamilton O, Scurr M, Collison AM, Mattes J, Allen KJ, Giraud AS.
    Am J Physiol Gastrointest Liver Physiol; 2016 Jan 01; 310(1):G13-25. PubMed ID: 26514775
    [Abstract] [Full Text] [Related]

  • 33. Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil trafficking into the esophagus.
    Zhang S, Wu X, Yu S.
    Dis Esophagus; 2014 Aug 01; 27(6):601-6. PubMed ID: 24165271
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment.
    Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, Parashette KR, Du J, Fillon S, Protheroe CA, Lee JJ, Amsden K, Melin-Aldana H, Capocelli KE, Furuta GT, Ackerman SJ.
    J Allergy Clin Immunol; 2012 May 01; 129(5):1387-1396.e7. PubMed ID: 22465212
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I.
    Cochrane Database Syst Rev; 2020 Dec 08; 12(12):CD013432. PubMed ID: 33295032
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Dec 08; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.